Afrezza Review Shows Need For Patient-Driven Endpoints In Diabetes
Executive Summary
Hemoglobin A1c levels are not particularly meaningful to patients more interested in heading off a hypoglycemia event, FDA advisory committee’s patient representative says. Panel votes to approve MannKind’s inhaled insulin despite agency’s efficacy questions and view that a hypoglycemia benefit was not shown.
You may also be interested in...
Diabetes Endpoints, CV Requirements Get Special Handling At FDA-Patient Meeting
FDA solves citizen petition with first-of-its-kind virtual patient meeting; diabetes group now hopes trifecta of requests will make it from Commissioner’s Office to top CDER officials.
How Afrezza’s Labeling Stacks Up To NovoLog and Exubera
MannKind’s inhaled insulin resulted in a lesser degree of hemoglobin A1c reduction than Novo Nordisk’s insulin aspart in a pivotal study in type 1 diabetics.
Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.